Credit Suisse’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2023
Q4 | – | Sell |
-200,000
| Closed | -$784K | – | 3192 |
|
2023
Q3 | $784K | Buy |
200,000
+19,480
| +11% | +$76.4K | ﹤0.01% | 2428 |
|
2023
Q2 | $181K | Sell |
180,520
-751
| -0.4% | -$751 | ﹤0.01% | 3093 |
|
2023
Q1 | $655K | Sell |
181,271
-2,648
| -1% | -$9.57K | ﹤0.01% | 2570 |
|
2022
Q4 | $5.92M | Buy |
183,919
+410
| +0.2% | +$13.2K | 0.01% | 1189 |
|
2022
Q3 | $7.67M | Sell |
183,509
-227
| -0.1% | -$9.49K | 0.01% | 1021 |
|
2022
Q2 | $7.75M | Sell |
183,736
-122
| -0.1% | -$5.15K | 0.01% | 1027 |
|
2022
Q1 | $12.5M | Buy |
183,858
+5,534
| +3% | +$375K | 0.01% | 932 |
|
2021
Q4 | $21.6M | Buy |
178,324
+12,778
| +8% | +$1.55M | 0.01% | 775 |
|
2021
Q3 | $23.3M | Buy |
165,546
+10,760
| +7% | +$1.52M | 0.01% | 755 |
|
2021
Q2 | $42.5M | Buy |
154,786
+5,357
| +4% | +$1.47M | 0.02% | 570 |
|
2021
Q1 | $32M | Buy |
149,429
+14,153
| +10% | +$3.03M | 0.02% | 679 |
|
2020
Q4 | $32.7M | Buy |
135,276
+9,807
| +8% | +$2.37M | 0.02% | 640 |
|
2020
Q3 | $13.2M | Buy |
125,469
+22
| +0% | +$2.32K | 0.01% | 884 |
|
2020
Q2 | $12.3M | Buy |
125,447
+50,441
| +67% | +$4.94M | 0.01% | 924 |
|
2020
Q1 | $5.63M | Buy |
75,006
+15,368
| +26% | +$1.15M | ﹤0.01% | 1137 |
|
2019
Q4 | $4.84M | Buy |
59,638
+1,473
| +3% | +$120K | ﹤0.01% | 1436 |
|
2019
Q3 | $7.1M | Buy |
58,165
+3,051
| +6% | +$372K | 0.01% | 1146 |
|
2019
Q2 | $9.9M | Sell |
55,114
-74
| -0.1% | -$13.3K | 0.01% | 999 |
|
2019
Q1 | $8.83M | Buy |
55,188
+54
| +0.1% | +$8.64K | 0.01% | 1004 |
|
2018
Q4 | $14.3M | Buy |
55,134
+10,720
| +24% | +$2.79M | 0.01% | 781 |
|
2018
Q3 | $10.8M | Buy |
44,414
+22,406
| +102% | +$5.46M | 0.01% | 998 |
|
2018
Q2 | $5.19M | Buy |
+22,008
| New | +$5.19M | 0.01% | 1416 |
|